This activity is expired and is no longer available for CME credit.


Neuromyelitis Optica Spectrum Disorder: Improving Diagnosis and Treatment

Author(s)/Faculty: Andrew G. Lee, MD; Heather E. Moss, MD, PhD; Prem S. Subramanian, MD, PhD
Release Date: 1/14/2021Expiration Date: 1/13/2022
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: VideoProvider:
Neuromyelitis optica spectrum disorder (NMOSD) is characterized by inflammation in the optic nerve and spinal cord. Diagnostic criteria of NMOSD have evolved and are now based on the presence of core clinical characteristics, NMO-specific aquaporin 4 (AQP4)-antibody status, and magnetic resonance imaging—which allows for a differential diagnosis. Until recently, treatment options for NMOSD have been limited, but there are now 3 US Food and Drug Administration-approved therapies for the treatment of NMOSD—with others under clinical evaluation. These approved and emerging therapy options have changed the treatment landscape for NMOSD by reducing the number of NMOSD relapses and enhancing clinical outcomes for these patients. Within this CME activity, experts in the field will review the pathophysiology of NMOSD and its burden in patients, summarize evidence-based diagnostic criteria and best practices for the differential diagnosis of NMOSD, as well as assess the efficacy of recently approved and emerging therapies for the treatment and prevention of NMOSD relapses.